Lack of pharmacokinetic interactions between cilomilast and theophylline or smoking in healthy volunteers

Journal of Clinical Pharmacology

Volumn 44, Issue 9, 2004, Pages 1046-1053

  Murdoch, Robert D ^a   Zussman, Barry ^a   Schofield, J Paul ^a   Webber, Dawn M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cilomilast; Drug interactions; Pharmacokinetics; Smokers and nonsmokers; Theophylline

Indexed keywords

CILOMILAST; PHOSPHODIESTERASE IV INHIBITOR; THEOPHYLLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CARDIOTOXICITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DYSPEPSIA; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SMOKING; URINARY TRACT DISEASE; VOMITING;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BRONCHODILATOR AGENTS; CARBOXYLIC ACIDS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; NITRILES; PHOSPHODIESTERASE INHIBITORS; SMOKING; THEOPHYLLINE;

EID: 4143107864     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004266488     Document Type: Article

References (20)

1. Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, et al: Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999;12:131-135.
2. Sturton G, Fitzgerald M: Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest 2002;121:192S-196S.
3. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG: Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci 1997;18:164-171.
4. Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, et al: Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:976-982.
5. Profita M, Chiappara G, Mirabella F, Di Giorgi R, Chimenti L, Costanzo G, et al: Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax 2003;58:573-579.
6. Johnston ID: Theophylline in the management of airflow obstruction: 2. Difficult drugs to use few clinical indications. Br Med J 1990;300:929-931.
7. Cazzola M, Donner CF, Matera MG: Long acting beta-2 agonists and theophylline in stable chronic obstructive pulmonary disease. Thorax 1999;54:730-736.
8. Barnes PJ: Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003;167:813-818.
9. Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. World Health Organization. 2001 (updated 2003).
10. Jonkman JH, Upton RA: Pharmacokinetic drug interactions with theophylline. Clin Pharmacokinet 1984;9:309-334.
11. Jonkman JH: Therapeutic consequences of drug interactions with theophylline pharmacokinetics. J Clin Immunol 1986:78:736-742.
12. Hay DW: Chronic obstructive pulmonary disease: emerging therapies. Curr Opin Chem Biol 2000:4:412-419.
13. Giembycz MA: Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2001;10:1361-1379.
14. Murdoch RD, Cowley H, Kelly J, Higgins R, Webber D: Cilomilast (Ariflo) does not potentiate the cardiovascular effects of inhaled salbutamol. Pulm Pharmacol Ther 200215:521-527.
15. Zussman BD, Kelly J, Murdoch RD, Clark DJ, Schubert C, et al: Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin. Clin Ther 2001;23:921-931.
16. Kelly J, Murdoch RD, Clark DJ, Webber DM, Fuder H: Warfarin pharmacodynamics unaffected by cilomilast. Ann Pharmacother 2001;35:1535-1539.
17. Burrows B, Knudson RJ, Cline MG, Lebowitz MD: Quantitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis 1977;115:195-205.
18. U.S. Department of Health and Human Services (DHHS): The Health Benefits of Smoking Cessation: A Report of the Surgeon General. Washington. DC: DHHS, 1990.
19. Hunt SN, Jusko WJ, Yurchak AM: Effect of smoking on theophylline disposition. Clin Pharmacol Ther 1976;19:546-551.
20. Johnston I, Jenkinson D: Are theophyllines being prescribed effectively and safety in general practice? Br J Clin Pract 1995;49:16-18.